KRP-A218 / Kyorin - LARVOL DELTA

PI4KB Inhibitor Ameliorates Exacerbation of Respiratory Diseases Caused by Rhinovirus Infection in Mice (ATS 2022) - "Inhibition of PI4KB showed broad antiviral activity against RV and ameliorated RV infection-induced exacerbation of pathological condition in asthma mouse model. Therefore, PI4KB inhibitor is expected to be a promising therapeutic agent for improving the exacerbation of respiratory disease caused by RV infection. Nonclinical package of KRP-A218 including GLP-Tox also supports the ongoing first-in-human study."

Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects (clinicaltrials.gov) - P1 | N=99 | Completed | Sponsor: Kyorin Pharmaceutical Co.,Ltd | Recruiting ➔ Completed

Trial completion

[VIRTUAL] KRP-A218, an Orally Active and Selective PI4KB Inhibitor with Broad-Spectrum Anti-Rhinovirus Activity, Has Potent Therapeutic Antiviral Activity in vivo (IDWeek 2021) - No abstract available

Preclinical • Infectious Disease